KR20240055743A - Mnk 억제제를 사용한 편두통 치료 방법 - Google Patents

Mnk 억제제를 사용한 편두통 치료 방법 Download PDF

Info

Publication number
KR20240055743A
KR20240055743A KR1020247007155A KR20247007155A KR20240055743A KR 20240055743 A KR20240055743 A KR 20240055743A KR 1020247007155 A KR1020247007155 A KR 1020247007155A KR 20247007155 A KR20247007155 A KR 20247007155A KR 20240055743 A KR20240055743 A KR 20240055743A
Authority
KR
South Korea
Prior art keywords
alkyl
branched
haloalkyl
hydroxyalkyl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247007155A
Other languages
English (en)
Korean (ko)
Inventor
테오도르 제이. 프라이스
제임스 제이. 산
Original Assignee
4이 테라퓨틱스, 인크.
더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 4이 테라퓨틱스, 인크., 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 filed Critical 4이 테라퓨틱스, 인크.
Publication of KR20240055743A publication Critical patent/KR20240055743A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020247007155A 2021-08-05 2022-08-05 Mnk 억제제를 사용한 편두통 치료 방법 Pending KR20240055743A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163229882P 2021-08-05 2021-08-05
US63/229,882 2021-08-05
PCT/US2022/039529 WO2023014943A1 (en) 2021-08-05 2022-08-05 Methods of treating migraine with mnk inhibitors

Publications (1)

Publication Number Publication Date
KR20240055743A true KR20240055743A (ko) 2024-04-29

Family

ID=85154787

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247007155A Pending KR20240055743A (ko) 2021-08-05 2022-08-05 Mnk 억제제를 사용한 편두통 치료 방법

Country Status (10)

Country Link
US (1) US20250205244A1 (https=)
EP (1) EP4380566A4 (https=)
JP (1) JP2024528982A (https=)
KR (1) KR20240055743A (https=)
CN (1) CN118076354A (https=)
AU (1) AU2022324472A1 (https=)
CA (1) CA3228265A1 (https=)
IL (1) IL310590A (https=)
MX (1) MX2024001560A (https=)
WO (1) WO2023014943A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4646266A1 (en) * 2023-01-04 2025-11-12 4E Therapeutics, Inc. Solid state forms of mnk inhibitors
CN116735759B (zh) * 2023-08-14 2023-11-07 南京威凯尔生物医药科技有限公司 一种高效液相色谱法检测乌布吉泮中间体及其对映体杂质的方法
WO2026006417A1 (en) * 2024-06-26 2026-01-02 4E Therapeutics, Inc. Formulations of mnk inhibitors
WO2026006453A1 (en) * 2024-06-26 2026-01-02 4E Therapeutics, Inc. Solid dispersion formulations of mnk inhibitors
WO2026006442A1 (en) * 2024-06-26 2026-01-02 4E Therapeutics, Inc. Deuterated mnk inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080039450A1 (en) * 2006-06-22 2008-02-14 Jensen Annika J Compounds
US10280168B2 (en) * 2012-03-30 2019-05-07 Agency For Science, Technology And Research Bicyclic heteroaryl derivatives as MNK1 and MNK2 modulators and uses thereof
TWI713455B (zh) * 2014-06-25 2020-12-21 美商伊凡克特治療公司 ＭｎＫ抑制劑及其相關方法
TW201831479A (zh) * 2017-01-20 2018-09-01 德商拜耳製藥公司 經取代二氫咪唑并吡啶二酮
US20190388425A1 (en) * 2017-01-20 2019-12-26 Bayer Pharma Aktiengesellschaft Substituted imidazopyridinpyrimidines
EP3972593B1 (en) * 2019-05-23 2025-07-02 Board of Regents, The University of Texas System Inhibitor of mnk for the treatment of neuropathic pain

Also Published As

Publication number Publication date
AU2022324472A1 (en) 2024-02-15
JP2024528982A (ja) 2024-08-01
EP4380566A4 (en) 2025-08-27
WO2023014943A1 (en) 2023-02-09
MX2024001560A (es) 2024-06-26
EP4380566A1 (en) 2024-06-12
US20250205244A1 (en) 2025-06-26
CA3228265A1 (en) 2023-02-09
IL310590A (en) 2024-04-01
CN118076354A (zh) 2024-05-24

Similar Documents

Publication Publication Date Title
US12110292B2 (en) Ligands to cereblon (CRBN)
KR20240055743A (ko) Mnk 억제제를 사용한 편두통 치료 방법
EP3651762B1 (en) Antagonists of the muscarinic acetylcholine receptor m4
US9186361B2 (en) Compounds and compositions for the treatment of parasitic diseases
US11414406B2 (en) Antagonists of the muscarinic acetylcholine receptor M4
TW201629063A (zh) 經取代胺基嘌呤化合物、其組合物及用其之治療方法
US9296754B2 (en) Compounds and compositions for the treatment of parasitic diseases
EP3697781B1 (en) Antagonists of the muscarinic acetylcholine receptor m4
US20230122344A1 (en) Antagonists of the muscarinic acetylcholine receptor m4
WO2023278686A1 (en) Spirocyclic pyridine-1,5-diones exhibiting mnk inhibition and their method of use
CA2932870C (en) [1,2,4]triazolo[1,5-a]pyrimidine derivatives as protozoan proteasome inhibitors for the treatment of parasitic diseases such as leishmaniasis
CA3217661A1 (en) Small molecule cyclin dependent kinase 4/6 (cdk4/6) and ikzf2 (helios) degraders and methods of use thereof
US20240010640A1 (en) Antagonists of the muscarinic acetylcholine receptor m4
JP2023533616A (ja) Ｍｎｋ阻害を示すピリジン－１，５－ジオン及びそれらの使用方法
US11078186B2 (en) ROR γ modulators
EP3464312A1 (en) Animal and human anti-trypanosomonal and anti-leishmania agents
KR20250005230A (ko) 신경염증성 병태를 치료하는 방법
CA3214360A1 (en) Pyrimidine derivatives useful as lrrk2 kinase inhibitors
US20260098030A1 (en) Negative allosteric modulators of metabotropic glutamate receptor 2
CN120757535A (zh) 含氧代吡啶并氧代脂肪环结构的化合物及其医药用途
WO2021106947A1 (ja) 新規キノン誘導体およびそれを有効成分とする抗トリパノソーマ剤

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000